44 results about "Blood platelet counts" patented technology

Disclosed herein are wound dressings comprising fibrinogen and at least one procoagulant such as propyl gallate in a therapeutic amount. Also disclosed are methods of treating wounds, increasing an amount of or rate of coagulation of blood from a wound, increasing an amount of or rate of clot formation over a wound, increasing blood platelet counts, activating a coagulation system, increasing the plasma concentration of fibrinogen, and decreasing the activated partial thromboplastin time. Also disclosed are an arterial bleeding model and methods of studying arterial bleeding.

The invention discloses a sample analyzing method which can detect visible components of urine, blood and other body fluid on the same instrument to perform blood red blood cell counting and morphological analysis, blood differential blood counting and blood platelet counting analysis. The method includes: determining detection flow; absorbing samples to be tested; inputting the samples to be tested into a testing area; testing the samples to be tested, and determining the visible components in the samples to be tested; and producing a report of the visible component corresponding to the samples to be tested according to the different samples to be tested. In the sample analyzing method, when the detection flow corresponding to the detection types is determined, users can absorb the samples to be tested and input the samples to be tested into the testing area so as to detect the samples to be tested according to the determined detection flow and determine the visible components in the samples to be tested. Finally the report of the visible components of the samples to be tested is produced, and testing on various indexes of the samples to be tested is achieved.

The invention relates to a non-invasive serological scoring model for hepatic fibrosis and a design method thereof. The model includes an input module, a processing module and an output module. The input module receives three independent predictors including blood platelet count, laminin and procollagen type 3. The processing module is connected with the input module and evaluates the situation ofhepatic fibrosis based on the independent predictors. The output module is connected with the processing module and outputs the score finally obtained by the module. The model can more accurately evaluate the situation of severe hepatic fibrosis for patients with chronic hepatitis. Compared with other models, the model only involves the three independent predictors including PLT, LN and PIIINP.The contained serological indicators are fewer, the accuracy and the practicability are higher, the model is more concise to use, popularization in clinical treatment and primary hospitals is facilitated, the probability of invasive examination is thus reduced, and the risk and burden of the patients are reduced.

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

The invention discloses a Zhuang medicine composition assisted in resisting lung cancer. The Zhuang medicine composition is characterized by being prepared from the following Zhuang medicinal materials: Nyarinngoux (Chinese name: baihuasheshecao), Gaeubwnhgauh (Chinese name: baiying), Byaekloekhauj (Chinese name: longkui), Buenqcilienz (Chinese name: banzhilian), Ginghgun (Chinese name: guangxi eshu), Fouxndoengz (Chinese name: shishangbai), Swnjgyaeujhenj (Chinese name: huanghuadaoshuilian), Raggongox (Chinese name: lugen), GO gyauhgujlanz (Chinese name: jiaogulan) and Lozhangoj (Chinese name: luohanguo). The Zhuang medicine composition is combined with chemical drugs for curing lung cancer, can reduce the toxic and side effects of inappetence caused by the chemical drugs, reduce the damage of the chemical drugs to immune organs, increase white blood cell count, blood platelet count, red blood cell count and hemoglobin count to reduce the inhibiting effect on myelosuppression, reduce the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase to alleviate the damage to liver functions and increase the tumor suppression function of the chemical drugs. Namely, the Zhuang medicine composition is combined with the chemical drugs for curing the lung cancer and has the effects of toxicity reducing and efficacy enhancing.

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as ET.

The present invention provides a platelet detection system based on an error prediction model. The system comprises a detection part, a control part and a re-detection part, wherein the detection part is used for detecting a portion of a sample based on impedance platelet count, the control part comprises a false positive judgment module, wherein the false positive judgment module can be used for judging by using an error prediction model based on data of the detection part, if the judgment is positive, the other part of the sample is added into the re-detection part for re-detection, and if the judgment is false positive, re-detection is not carried out any more; and the re-detection part is configured to detect the other portion of the sample by using a fluorescence platelet count (PLT-F).

The invention relates to application of ginsenoside in the pharmacy field, in particular to application of ginsenoside in preparing antiphospholipid syndrome molecular targeting treatment medicine. In a laboratory antiphospholipid syndrome mouse model, the compound can effectively lower the level of anticardiolipin antibodies, anti-beta2-GP1 antibodies and lupus anticoagulants in blood; meanwhile, in a pregnant mouse model, the compound effectively lower aCL activation, shortens partial thromboplastin time and reduces the blood platelet count and the abortion rate; safety study shows that the compound is high in safety, has no influence on the central nervous system, the cardiovascular system and the respiratory system and has no mutagenic action. It is indicated that the compound has high safety and a good inhibiting effect on the antiphospholipid syndrome at the test dose and can be used for treating the antiphospholipid syndrome.

The invention relates to a traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura. The traditional Chinese medicine composition is prepared from the following raw pharmaceutical materials in parts by weight: 20-28 parts of raw milkvetch root, 15-20 parts of prepared ligustrum lucidum, 10-15 parts of atractylodes macrocephala, 12-18 parts of raw rehmannia root, 15-20 parts of dodder seed, 12-18 parts of tree peony bark, 12-18 parts of Jiangnan herba selaginellae, 12-18 parts of herba agrimoniae, 12-18 parts of aizoon stonecrop and 4-8 parts of prepared liquorice root. The invention further provides application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the compatibility of the traditional Chinese medicine composition disclosed by the invention accords with the principle of monarch-and-minister-and-assistant-and-guide of the traditional Chinese medicine, the traditional Chinese medicine composition can effectively control the bleeding symptom of a sufferer, improve the quality of life and increase the number of platelets and has a remarkable treatment effect on idiopathic thrombocytopenic purpura, and no adverse reaction is caused, so that the traditional Chinese medicine composition has broad development and application prospects and is suitable for further popularization and application.

A blood detection method is provided, including: treating a blood sample with a first reagent to obtain a test sample, wherein the first reagent includes a hemolytic agent for lysing red blood cells in the blood sample into fragments having light scattering characteristics significantly different from those of platelets; passing particles in the test sample through a detection area of an optical detection system one by one, to obtain optical information of the test sample; and obtaining optical information of platelets according to at least two types of the optical information of the test sample. In the method, a platelet count is obtained by lysing red blood cells in a blood sample, and white blood cell subpopulations can be also differentiated.

The invention discloses application of an artemisinin compound in preparation of drugs for treating ITP. It is unexpectedly discovered in clinical trials that blood platelet count holding time can beprolonged when drugs of artemisinin, especially artesunate or dihydroartemisinin treat patients with immune thrombocytopenia and patients with relapse of the immune thrombocytopenia, and it is indicated that the artemisinin drugs have a good therapeutic effect on the immune thrombocytopenia. Further studies show that the combination of the artemisinin drugs and other drugs, such as the combinationof the artemisinin drugs and glucocorticoids, can further reduce the dosage of glucocorticoid, gamma globulin and the like for treatment, thereby reducing the treatment cost of the patients and reducing the probability of significant complications. Reticulocytes as a toxicity sensitive index of the artemisinin drugs are strictly observed by the inventor, it is found that no significant differenceexists before and after the treatment, and it is further showed that the artemisinin drugs have good safety.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation for treating idiopathic thrombocytopenic purpura. The preparation is prepared from the following raw materials in parts by weight: 5 to 20 parts of pig nail, 3 to 12 parts of rhizoma rehmanniae, 2 to 10 parts of radix paeoniae rubra, and 2 to 10 parts of cortex moutan radicis boiled by juice of radix rehmanniae recen. The preparation for treating the idiopathic thrombocytopenic purpura has the advantages that the treatment effect is obvious; after the preparation is taken for three courses, the subcutaneous purpura and other symptoms are basically eliminated, and the blood platelet count is obviously increased; the function of obviously enhancing the immunity of the human body is realized, the preparation is especially suitable for female patients with menometrorrhagia symptoms, and is free of any toxic or side effect, and the application range is broad.

The present disclosure provides for compositions and methods for managing female infertility, caused by diminished ovarian reserve. More particularly, the present disclosure provides a platelet rich plasma (PRP) having one or more of significantly higher platelet count and significantly low RBC and WBC count as compared to the starting blood, and a method to arrive at the same. Consequently, a growth factor concentrate derived from the PRP and a method to arrive at the same are provided. Further provided, along with therapeutic applications for treatment of infertility caused by diminished ovarian reserve are also provided.

The invention discloses a preparation method of a novel platelet quality control product and application of the platelet quality control product prepared by the method. The method comprises the following steps: (1) adding an anticoagulant into animal whole blood, and performing centrifuging to obtain platelet-rich plasma; (2) centrifuging the platelet-rich plasma again to obtain upper-layer platelet-depleted plasma and bottom platelets, washing and centrifuging the bottom platelets for multiple times to obtain concentrated platelets, adding a loading solution, performing water bath at 37 DEG C, and performing centrifuging to obtain platelets loaded with a protective agent; and (3) adding a freeze-drying buffer solution into the platelets loaded with the protective agent, performing pre-freezing for 18-36 hours at the temperature of-60 DEG C to-80 DEG C, and then carrying out freeze-drying; and storing the freeze-dried powder at 2-8 DEG C. The platelet quality control product prepared by the method not only can be used for platelet counting, but also can be suitable for platelet in-vitro adhesion function and aggregation function detection.

The invention discloses a prognosis model for gram-negative bacillus blood flow infection of a tumor patient. The prognosis model comprises a plurality of optimal prognosis factors, evaluation scores corresponding to the optimal prognosis factors in different states and a survival probability corresponding to a total score obtained by adding the evaluation scores, wherein the prognosis factors mainly comprise platelet counting, lymphocyte counting, ICU (Intensive Care Unit), pulmonary infection and shock; wherein the optimal prognosis factors in different states include different counts of platelets before death of a gram-negative bacillus blood flow infected tumor patient, different counts of lymphocytes before death of the gram-negative bacillus blood flow infected tumor patient, different counts of the platelets before death of the gram-negative bacillus blood flow infected tumor patient, whether a gram-negative bacillus bloodstream infected tumor patient enters the ICU prior to death, whether a gram-negative bacillus bloodstream infected tumor patient has the shock prior to death, and whether a tumor patient has the pulmonary infection prior to being infected with gram-negative bacillus bloodstream infection. By means of the method, the death risk of the patient can be quickly, timely and accurately predicted.